Pharmacological activation of the p53 pathway by a new compound CYZ2017 exerts anti-tumor effects

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The p53-MDM2 protein-protein interaction is a key target for cancer drug development, particularly in wild-type p53 cancers.
• Inhibiting this interaction can restore p53 tumor-suppressive functions.

Purpose of the Study:

• To introduce and characterize a novel inhibitor, CYZ2017, targeting the p53-MDM2 interaction.
• To evaluate the anti-cancer efficacy and safety profile of CYZ2017.

Main Methods:

• In vitro studies assessing p53 nuclear translocation, p53 target gene (p21) activation, cell cycle arrest, and apoptosis.
• In vivo evaluation using a HCT116 xenograft mouse model.

Main Results:

• CYZ2017 induced p53 nuclear translocation and p53-dependent anti-proliferation activity in various cancer cells.
• CYZ2017 treatment increased p53 levels, upregulated p21, and caused G0/G1 cell cycle arrest and apoptosis in HCT116 cells.
• CYZ2017 suppressed tumor growth in a HCT116 xenograft model with no apparent toxicity.

Conclusions:

• CYZ2017 is a potent p53-MDM2 interaction inhibitor with significant anti-tumor activity.
• CYZ2017 demonstrates potential as a therapeutic agent for cancers with wild-type p53.
• Further research into p53-MDM2 interaction inhibitors is warranted for novel anti-cancer drug development.